US6551610B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Multifaceted compositions for post-surgical adhesion prevention
Assignee: Poly Med Inc
•
Filing: 2002-04-24
•
Granted: 2003-04-22
•
Expires: 2022-04-24
Abstract
Abstract This invention deals with an absorbable, gel-forming composition for multifaceted prevention of post-operative surgical adhesion through a plurality of physico-pharmacological modes, comprising a solution of one or more bioactive compounds in a liquid copolymeric vehicle made by end-grafting one or more cyclic monomer onto a polyalkylene glycol. More specifically, the bioactive drugs can display one or more pharmacological activity associated with antiangiogenic, antineoplastic, anti-inflammatory, and anti-proliferative effects.
Inventors
- 👤 Shalaby W. Shalaby
- 👤 Waleed S. W. Shalaby
- 👤 Marc Shalaby
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 15:50
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K47/00; A61K47/30; A61K47/34; A61K47/50; A61K47/51; A61K47/56; A61K47/59; A61K47/593; A61K47/60; A61L; A61L24/00; A61L24/04; A61L24/046; A61L26/00; A61L26/0009; A61L26/0019; A61L26/0052; A61L26/0061; A61L26/008; A61L31/00; A61L31/04; A61L31/041; A61L31/06; A61L31/14; A61L31/145; C; C08; C08G; C08G63/00; C08G63/64; C08G63/66; C08G63/664
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
41 words
An absorbable, liquid, gel-forming composition for multifaceted prevention of post-operative surgical adhesion through a plurality of physicopharmacological modes comprising a solution of one or more bioactive compound in a copolymerization product of polyalkylene glycol end-grafted with one or more cyclic monomer.
Claim 2
Dependent Claim
41 words
An absorbable, liquid, gel-forming composition for multifaceted prevention of post-operative surgical adhesion through a plurality of physicopharmacological modes comprising a solution of one or more bioactive compound in a copolymerization product of polyalkylene glycol end-grafted with one or more cyclic monomer.
Claim 3
Dependent Claim
17 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein end-grafted polyalkylene glycol is a polyethylene glycol.
Claim 4
Dependent Claim
23 words
An absorbable, liquid, gel-forming composition as in claim 2 wherein the polyethylene glycol is end-grafted with a mixture of trimethylene carbonate and glycolide.
Claim 5
Dependent Claim
26 words
An absorbable, liquid, gel-forming composition as in claim 3 wherein end-grafted polyethylene glycol is a mixture of two or more types having significantly different polyether/copolyester ratios.
Claim 6
Dependent Claim
22 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein the bioactive agent is polypeptide comprising 6 to 32 amino acid sequences.
Claim 7
Dependent Claim
16 words
An absorbable, liquid, gel-forming composition as in claim 5 wherein the polypeptide is a somatostatin analog.
Claim 8
Dependent Claim
24 words
An absorbable, liquid, gel-forming composition as in claim 6 wherein the somatostatin analog is a cyclic octapeptide at a concentration up to 0.5 mg/mL.
Claim 9
Dependent Claim
15 words
An absorbable, liquid, gel-forming composition as in claim 7 wherein the cyclic octapeptide comprises lanreotide.
Claim 10
Dependent Claim
20 words
An absorbable, liquid, gel-forming composition as in claim 5 wherein the polypeptide is a lutenizing human releasing hormone (LHRH) analog.
Claim 11
Dependent Claim
22 words
An absorbable, liquid, gel-forming composition as in claim 9 wherein the LHRH analog concentration in the vehicle is less than 0.5 mg/mL.
Claim 12
Dependent Claim
22 words
An absorbable, liquid, gel-forming composition as in claim 4 wherein the intrachain or terminal sequences are chemically modified to produce carboxyl-bearing molecules.
Claim 13
Dependent Claim
25 words
An absorbable, liquid, gel-forming composition as in claim 11 wherein at least a fraction of the carboxylic group forms ionic conjugates with a bioactive peptide.
Claim 14
Dependent Claim
26 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein the bioactive agent is a basic polypeptide that is ionically conjugated with a carboxyl-bearing bioactive agent.
Claim 15
Dependent Claim
27 words
An absorbable, liquid, gel-forming composition as in claim 13 wherein the polypeptide comprises 6 to 32 amino acid sequences and the carboxyl-bearing bioactive agent is an NSAID.
Claim 16
Dependent Claim
16 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein the bioactive agent comprises an NSAID.
Claim 17
Dependent Claim
17 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein the bioactive agent comprises an antineoplastic compound.
Claim 18
Dependent Claim
19 words
An absorbable, liquid, gel-forming composition as in claim 1 wherein the bioactive agent has more than one pharmacological function.
Claim 19
Dependent Claim
14 words
An absorbable, liquid, gel-forming composition as in claim 14 wherein the NSAID comprises naproxen.
Claim 20
Dependent Claim
21 words
An absorbable, liquid, gel-forming composition as in claim 8 wherein the lanreotide concentration in the gel-forming vehicle is about 0.25 mg/mL.
Claim 21
Dependent Claim
14 words
An absorbable, liquid, gel-forming composition as in claim 15 wherein the NSAID comprises naproxen.
Claim 22
Dependent Claim
15 words
An absorbable, liquid, gel-forming composition as in claim 16 wherein the antineoplastic compound comprises paclitaxel.
Claim 23
Dependent Claim
15 words
An absorbable, liquid, gel-forming composition as in claim 17 wherein the bioactive agent comprises trapidil.
References Cited (Backward Citations)
US3991766A
Cited
US4141973A
Cited
US4141973B1
Cited
US4209607A
Cited
US4226243A
Cited
US4369229A
Cited
US4532134A
Cited
US5385738A
Cited
US4937254A
Cited
US4937254B1
Cited
US5011692A
Cited
US4919939A
Cited
US4938763A
Cited
US4938763B1
Cited
US5278201A
Cited
US5135752A
Cited
US4911926A
Cited
US5366733A
Cited
US5171148A
Cited
US5077049A
Cited
US5093319A
Cited
US4994277A
Cited
US5198220A
Cited
US5366756A
Cited
US5866544A
Cited
US5612052A
Cited
US5714159A
Cited
US6037331A
Cited
US6413539B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2006-04-21 | 2006-10-21 | 2007-04-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2010-04-21 | 2010-10-21 | 2011-04-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2014-04-21 | 2014-10-21 | 2015-04-22 | $7700.00 | Window Closed / Lapsed |